5-Hydroxytryptamine Receptors as Targets for Drug Therapies of Vascular-Related Diseases
-
- Gamoh Shuji
- First Department of Pharmacology, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare
-
- Hisa Hiroaki
- Second Department of Pharmacology, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare
-
- Yamamoto Ryuichi
- First Department of Pharmacology, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare
Search this article
Abstract
5-Hydroxytryptamine (5-HT) is involved in regulation of both physiological and pathophysiological conditions in tissues throughout the body. 5-HT induces vascular smooth muscle constriction in most vessels. The vasoconstrictive effects of 5-HT are mediated by 5-HT1B and 5-HT2A receptors located on the membrane of smooth muscle cells, except in the intracranial arteries which constrict only through 5-HT1B receptors. 5-HT also acts as vasodilator because it releases nitric oxide from endothelial cells. This response is dominantly mediated by 5-HT1B receptors but not by 5-HT2A receptors. In this review, we focus on the action of 5-HT via G protein-coupled 5-HT receptors involved in some vascular-related pathophysiological responses. Furthermore, we describe the possibilities of 5-HT receptors as targets for drug therapy against saphenous vein grafts diseases (especially in patients with diabetes mellitus), migraine and pulmonary arterial hypertension.
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 36 (9), 1410-1415, 2013
The Pharmaceutical Society of Japan
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679609690496
-
- NII Article ID
- 130003361522
-
- NII Book ID
- AA10885497
-
- COI
- 1:STN:280:DC%2BC3sbksFCqtQ%3D%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL BIB ID
- 024791815
-
- PubMed
- 23995651
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed